Taxanes in the adjuvant therapy of breast cancer with positive nodes: A meta-analysis;Taxanos en el tratamiento adyuvante del cáncer de mama con ganglios positivos: Metanálisis

Farmacia Hospitalaria

Volumn 29, Issue 2, 2005, Pages 75-85

  Giménez Poderós, Teresa ^a   Gaminde Inda, I ^b   Iruin Sanz, A ^a   Napal Lecumberri, V ^a  

^a Instituto de Investigación Sanitaria de Navarra   (Spain)

^b Investigacion y Desarrollo Sanitarios   (Spain)

Author keywords

Adjuvant; Breast cancer; Meta analysis; Positive node; Taxane

Indexed keywords

TAXANE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DECISION MAKING; DRUG EFFICACY; DRUG USE; HUMAN; INFORMATION PROCESSING; META ANALYSIS; METASTASIS; PHASE 3 CLINICAL TRIAL; TREATMENT OUTCOME;

EID: 21044432760     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1130-6343(05)73642-4     Document Type: Article

References (40)

1. Organización Mundial de la Salud. Datos y cifras. Informe sobre la salud del mundo 2003. Disponible en: http://www.who.int/whr/2003/en/ Facts_and_Figures-es.pdf (Con acceso el 30 marzo 2004).
2. Dixon JM, Gregory K, Johnston S, Rodger A. Breast cancer (non-metastatic). Clin Evid 2003; 9: 1940-70.
3. Herman R, Hellman S. Clinical progression of breast cancer malignant behaviour: what to expect and when to expect it. J Clin Oncol 2000; 18: 591-9.
4. Levine MN, Olivotto IA, Fields ALA, Bowman DM, Bouchard F, McGregor M, et al. Adjuvant systemic therapy for women with node-positive breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. CMAJ 1998; 158 (Supl. 3): S52-64.
5. Early Breast Cancer Trialists Collaborative Group. Polichemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998; 352: 930-42.
6. Nabholtz JM, Riva A. Taxane/Anthracycline Combinations: Setting a New Standard in Breast Cancer? The Oncologist 2001; 6 (Supl. 3): 5-12.
7. Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999; 17: 2341-54.
8. Bishop JF, Dewar J, Toner GC, Smith J, Martin HN, Tattersall MH, et al. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol 1999; 17: 2355-64.
9. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, et al. Phase III Trial of Doxorubicin, Paclitaxel and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193). J Clin Oncol 2003; 21: 588-92.
10. Nabholtz J-M, Falkson C, Campos D, Szanto J, Martin M, Chan S, et al. Docetaxel and Doxorubicin compared with Doxorubicin and Cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phaseIII trial. J Clin Oncol 2003; 21: 968-75.
11. Jassem J, Pienkowski T, Pluzanska A, Jelic S, Gorbunova V, Mrsic-Krmpotic Z, et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as fisrt-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J clin Oncol 2001; 19: 1707-15.
12. Moher D, Cook D, Eastwood S, Olkin I, Rennie D, Stroup D, for the QUORUM Group. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUORUM statement. The Lancet 1999; 354: 1986-00.
13. American Association for Clinical Oncology (ASCO) [http://www.asco.org]. Abstracts del congreso 2003. Chicago (Illinois, EEUU). Disponible en: http://www.asco.org/ac/1,1003,_12-002387-00_18-0023,00.asp (citado el 20 de enero de 2004).
14. San Antonio Breast Cancer Symposium [http://www.sabcs.org]. Abstracts del congreso 2003. San Antonio (Texas, EE.UU.) http://www.sabcs.org/ SymposiumOnline/index.asp#abstracts (citado el 20 de enero de 2004).
15. Miami Breast Cancer Conference [http://www.breastcancerupdate.com]. Abstracts del congreso 2003. Miami (Florida, EEUU). Disponible en: http://www.breastcancerupdate.com/miamiconference2003/posters.htm (citado el 20 de enero de 2004).
16. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21: 976-83.
17. Clarke M, Oxman AD, editores. Evaluación de calidad de los estudios. Manual del Revisor Cochrane 4.1.6 [actualización enero 2003]. Sección 6. http://www.cochrane.dk/cochrane/handbook/handbook.htm (con acceso el 31 de enero de 2003).
18. Petitti DB. Meta-analysis, decision analysis and cost-effectiveness analysis: methods for quantitative synthesis in medicine. New York: Oxford University Press, 1994.
19. Mamounas EP, Bryant J, Lembersky C, Fisher B, Atkins JN, Fehrenbacher L, et al. Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. ASCO Online (American Society of Clinical Oncology). American Society of Clinical Oncology 2003: Abstract 12.
20. Mamounas EP. Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. Session Early Breast Cancer. 2003 ASCO annual meeting. Disponible en:http://www.asco.org/ac/1,1003,_12-002511-00_18-0023-00_19-002929,00.asp (citado 31 marzo 2004).
21. Nabholtz JM, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Vogel C, et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. ASCO Online (American Society of Clinical Oncology). American Society of Clinical Oncology 2002: Abstract 141.
22. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, et al. TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001: 55 months follow up. Program and abstracts of the 26th Annual Symposium of the American Society of Breast Disease. Dallas, Texas; April 11-13, 2003: Abstract 43.
23. Breast Cancer International Research Group (BCIRG) [http://www.bcirg.org/ ]. Información de estudio BCIRG 001. Disponible en: http://www.bcirg.org/ Internet/Studies/BCIRG+001.htm (citado el 31 marzo 2004).
24. Buzdar AU, Singletary SE, Valero V, Bóxer DJ, Ibrahim NK, Rahman Z, et al. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res 2002; 8: 1073-9.
25. Boér K, Láng I, Juhos É, Pintér T, Szántó J. Docetaxel kombinációs kezeléssel (TAC) szerzertt tapasztalataink az emlórák adjuváns kemoterápiájában. BCIRG 001 randomizált, multicentrikus fazes III vizsgálat hazai eredményei. Magyar Onkológia 2003; 47: 141-8.
26. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statist Med 1998; 17: 2815-34.
27. Davidson NE. Ongoing US Cooperative Group Trials using taxanes in the adjuvant setting. Clinical Breast Cancer 2002; 3 (Supl 2): S53-8.
28. Hudis C. Adjuvant use of taxanes for patients with breast cancer: we see the tip of the iceberg. Clinical Breast Cancer 2002; 3: 326-32.
29. Levine MN, Bramwhell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J Clin Oncol 1998; 16: 2651-8.
30. Fumoleau P, Bonneterre J, Luporsi E. Adjuvant chemotherapy for node-positive breast cancer patients: which is the reference today? J Clin Oncol 2003; 21: 1190-1; author reply 1191-2.
31. Piccart MJ, Lohrisch C, Duchateau L, Buyse M. Taxanes in the adjuvant treatment of breast cancer: why not yet? J Natl Cancer Inst Monogr 2001; 88-95.
32. Fumoleau P, Bremond A, Kerbrat P, Fargeot P, Namer M, Montcuquet P, et al. Better outcome of premenopausal node-positive (N+) breast cancer patients (pts) treated with 6 cycles vs 3 cycles of adjuvant chemotherapy: Eight year follow-up results of FASG 01. ASCO Online (American Society of Clinical Oncology). American Society of Clinical Oncology 1999: Abstract 252.
33. Gehl J, Boesgaard M, Paaske T, Vittrup Jensen B, Dombernowsky P. Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol 1996; 7: 687-93.
34. Gianni L, Vigano L, Locatelli A, Capri G, Giani A, Tarenzi E, et al. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 1997; 15: 1906-15.
35. Bellott R, Robert J, Dieras V, Misset JL, Baille P, Bozec L, et al. Taxotere (T) does not change the pharmacokinetic (PK) profile of doxorubicin (Dox) and doxorubicinol (Dx-ol). ASCO Online (American Society of Clinical Oncology). American Society of Clinical Oncology, 1998: Abstract 853.
36. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21: 1431-9.
37. Fe de erratas en: J Clin Oncol 2003; 21: 2226.
38. Pater JL, Pritchard KL. Optimal chemotherapy for women with breast cancer: the plot thickens. J Clin Oncol 2003; 21: 963-4.
39. Bryce C, Kennecke H, Chia S, Ragaz J. Benefit of Paclitaxel in estrogen receptor-negative versus estrogen receptor-positive early breast cancer. J Clin Oncol 2003; 21: 4465; author reply 4465-6.
40. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 2001; 93: 979-89.